Assessing quality of life in patients with head and neck cancer - Cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) quality of life head and neck module (QLQ-H&N35)
Ac. Sherman et al., Assessing quality of life in patients with head and neck cancer - Cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) quality of life head and neck module (QLQ-H&N35), ARCH OTOLAR, 126(4), 2000, pp. 459-467
Objective: To evaluate the reliability and validity of a new, disease-speci
fic quality-of-life measure for patients with head and neck cancer: the Eur
opean Organization for Research and Treatment of Cancer (EORTC) Quality of
Life Questionnaire-QLQ-H&N35.
Design: Cross-sectional study using questionnaire data and medical chart re
view.
Setting: Academic tertiary care otolaryngology clinic.
Participants: One hundred twenty ambulatory patients, including 30 patients
with advanced head and neck cancer in each of the following stages of trea
tment: (1) prior to treatment, (2) during active treatment, (3) within 6 mo
nths of completing treatment, and (4) more than 6 months after completing t
reatment. In addition, (5) a comparison group of 40 patients without malign
ant disease was included (total sample, N = 160).
Main Outcome Measures: Scores on EORTC Quality of Life Core Questionnaire (
QLQ-C30) and head and neck module (QLQ-H&N35), Profile of Mood States, and
Impact of Events Scale.
Results: The QLQ-H&N35 demonstrated acceptable reliability (internal consis
tency). It successfully discriminated between cancer patients and the compa
rison group, and among subgroups of cancer patients at different phases of
treatment (construct validity). The instrument was sensitive to the effects
of radiation treatment and to site of disease. Its low-to-moderate correla
tions with the EORTC core questionnaire indicated that the QLQ-H&N35 provid
ed unique information (discriminant validity). Scores were significantly as
sociated with a number of demographic variables.
Conclusion: Results support the use of this disease-specific measure to ass
ess quality of life among patients with advanced head and neck cancer.